Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Workman

Showing results (101-110 of 315) with videos related to

Pageof 32
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2008
Biomarkers in early clinical trials: the committed and the skepticsUdai Banerji, Johann de Bono, Ian Judson, et al.
Cell|February 11, 2017
How Much Longer Will We Put Up With $100,000 Cancer Drugs?Paul Workman, Giulio F Draetta, Jan H M Schellens, et al.
Journal of Biomolecular Screening|July 10, 2012
Small-molecule inhibitors of the protein methyltransferase SET7/9 identified in a high-throughput screenNicola-Jane Francis, Martin Rowlands, Paul Workman, et al.
Cell Cycle (Georgetown, Tex.)|November 11, 2009
Drugging the heat shock factor 1 pathway: exploitation of the critical cancer cell dependence on the guardian of the proteomeEmmanuel de Billy, Marissa V Powers, Jennifer R Smith, et al.
JAMA Ophthalmology|March 5, 2026
Intracameral Cefuroxime Use in Cataract Surgery After Penicillin Allergy ReclassificationKarthik Reddy, Paul Workman, Greg Eschenauer, et al.
Cancer Research|January 20, 2004
The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathwaySteven R Whittaker, Mike I Walton, Michelle D Garrett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2002
Establishment and characterization of acquired resistance to the farnesyl protein transferase inhibitor R115777 in a human colon cancer cell lineVictoria Smith, Martin G Rowlands, Elaine Barrie, et al.
Nature Reviews. Clinical Oncology|March 25, 2021
Applications of liquid biopsy in the Pharmacological Audit Trail for anticancer drug developmentAbhijit Pal, Rajiv Shinde, Manuel Selvi Miralles, et al.
Nature Reviews. Cancer|June 11, 2010
Envisioning the future of early anticancer drug developmentTimothy A Yap, Shahneen K Sandhu, Paul Workman, et al.
Progress in Cell Cycle Research|November 5, 2003
The contemporary drug development process: advances and challenges in preclinical and clinical developmentMichelle D Garrett, Mike I Walton, Edward McDonald, et al.
Pageof 32

Showing results (101-110 of 315) with videos related to

Sort By:
Pageof 32
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2008
Biomarkers in early clinical trials: the committed and the skepticsUdai Banerji, Johann de Bono, Ian Judson, et al.
Cell|February 11, 2017
How Much Longer Will We Put Up With $100,000 Cancer Drugs?Paul Workman, Giulio F Draetta, Jan H M Schellens, et al.
Journal of Biomolecular Screening|July 10, 2012
Small-molecule inhibitors of the protein methyltransferase SET7/9 identified in a high-throughput screenNicola-Jane Francis, Martin Rowlands, Paul Workman, et al.
Cell Cycle (Georgetown, Tex.)|November 11, 2009
Drugging the heat shock factor 1 pathway: exploitation of the critical cancer cell dependence on the guardian of the proteomeEmmanuel de Billy, Marissa V Powers, Jennifer R Smith, et al.
JAMA Ophthalmology|March 5, 2026
Intracameral Cefuroxime Use in Cataract Surgery After Penicillin Allergy ReclassificationKarthik Reddy, Paul Workman, Greg Eschenauer, et al.
Cancer Research|January 20, 2004
The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathwaySteven R Whittaker, Mike I Walton, Michelle D Garrett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2002
Establishment and characterization of acquired resistance to the farnesyl protein transferase inhibitor R115777 in a human colon cancer cell lineVictoria Smith, Martin G Rowlands, Elaine Barrie, et al.
Nature Reviews. Clinical Oncology|March 25, 2021
Applications of liquid biopsy in the Pharmacological Audit Trail for anticancer drug developmentAbhijit Pal, Rajiv Shinde, Manuel Selvi Miralles, et al.
Nature Reviews. Cancer|June 11, 2010
Envisioning the future of early anticancer drug developmentTimothy A Yap, Shahneen K Sandhu, Paul Workman, et al.
Progress in Cell Cycle Research|November 5, 2003
The contemporary drug development process: advances and challenges in preclinical and clinical developmentMichelle D Garrett, Mike I Walton, Edward McDonald, et al.
Pageof 32